Methods for delivering therapeutic amounts of glutamate to the CNS while simultaneously protecting against its excito-toxic effects are provided. Ibogaine is claimed as a NMDA chennel blocker.
Delivery devices and methods to maximize safety for implantation of a disc shunt and to infuse drugs, nutrients, buffer agents or growth factors through the disc shunt to treat back pain.
The present invention is directed to the treatment of chemical substance abuse and withdrawal symptoms, especially withdrawal symptoms associated with opioids, utilizing a combination of an effective amount of a cannabinoid, in particular, cannabidiol (CBD) and/or A9-tetrahydrocannabinol (THC) in combination with low dosage noribogaine or a derivative salt, solvate or ansolvate thereof to treat withdrawal symptoms, both acute and longer term. It has unexpectedly been discovered that the cannabinoids as described herein work in conjunction with noribogaine to synergistically ameliorate and/or attenuate chemical substance abuse, especially including opioid withdrawal symptoms, both acute and longer term symptoms, such that low dose noribogaine (often in daily dosages of 30 milligrams or less) may be favorably co-administered to a patient suffering from withdrawal symptoms, substantially shortening the QT interval of the patient and providing for a particularly safe and effective method to treat opioid withdrawal symptoms.
Methods and compositions related to therapeutic uses of ibogaine, an aibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
A mehtod of administering noribogaine to a human patient having drug addiction. Focus on utilizing dosages that provide efficacy without “significant deleterious clinical signs.”
Compositions of deuterated morphine derivatives and other active ingredients such as ibogaine.
Topical compositions containing macqui berry or macqui berry extract in combination with other active ingredients for the prevention and/or treatment of damage to skin.
Compositions comprising monoamine neurotransmitter uptake inhibitors and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of a variety of disorders. In some embodiments compositions include NMDA modulators.
Methods of treating Alzheimer’s disease using compositions including NMDA receptor antagonists such as ibogaine.
A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising co-administering an effective amount of mangiferin, norathyriol, and other ingredients, including ibogaine.